Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | DESTINY update: achieving TFR by de-escalating TKI therapy in CML

Mhairi Copland • 15 Nov 2019
MPN Advances Day 2019
Chronic Myeloid Leukemia Leukemia Dasatinib Imatinib Nilotinib
DESTINY

Mhairi Copland, MB ChB, PhD, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the DESTINY trial (NCT01804985). This trial aimed to examine the effects of gradual treatment withdrawal and whether TFR is feasible for chronic myeloid leukemia (CML) patients with less deep but stable remission. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Mhairi Copland

Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
How the management of CML is evolving & future directions
1:18
How the management of CML is evolving & future directions
Mhairi Copland • 5 Sep 2025
Current and future treatment strategies for blast-phase CML
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
The importance of improving treatment-free remission in patients with CML
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals